newsfilter
← Latest News
Business Wire·

Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update

– Passed Interim Futility Analysis of the Primary Endpoint in Phase 3 SELECT-MDS-1 Trial of Tamibarotene; Pivotal CR Data Expected by Mid-4Q 2024; Company to Host HR-MDS-focused Webcast Event with Medical Experts on